Skip to main content
editor@jprims.in
9343055451
e-ISSN: 3049-1681
Journal of Pharmaceutical Research and Integrated Medical Sciences

Journal of Pharmaceutical Research and Integrated Medical Sciences

Arpan Kumar Tripathi

Author Profile
Kamla Institute of Pharmaceutical Sciences, Shri Shankaracharya Professional University, Junwani, Bhilai, Chhattisgarh, India
3
Publications
1
Years Active
4
Collaborators
104
Citations

Publications by Arpan Kumar Tripathi

3 publications found • Active 2026–2026

2026

3 publications

Ethanolic Leaf Extract of Chenopodium album Linn. Attenuates Calcium Oxalate-Associated Urolithiasis in Rats: An Integrated In Vitro and In Vivo Evaluation

with Yashika, Deleshwar Kumar
11/17/2026
pp. 27-40

Background: The primary stone component in urolithiasis, a recurrent urinary tract disease characterized by crystal nucleation, development, aggregation, and retention, is calcium oxalate (CaOx). Chenopodium album Linn. has a long history of ethnomedical use for urinary and renal issues and has demonstrated an initial anti-crystallization effect. However, little information is known about the relationship between in vivo renal and urinary outcomes and in vitro CaOx crystallization. Objective: This study evaluated the anti-urolithiatic potential of an ethanolic leaf extract of C. album (EECA) using complementary in vitro and in vivo techniques. Methods: The leaves were subjected to Soxhlet extraction using ethanol to obtain a 6.0% w/w extract, and preliminary phytochemical screening was carried out. The nucleation of CaOx was measured at 10–100 mg/mL, and the inhibition of crystal growth was also examined. The standard treatment was cystone (750 mg/kg). EECA was given at doses of 50 and 200 mg/kg to rats with urolithiasis associated with calcium oxalate. Urinary uric acid, urine volume, and renal histology were determined. Results: EECA inhibited CaOx nucleation in a concentration-dependent manner by 18.75% at 10 mg/mL and 77.50% at 100 mg/mL. Inhibition at 100 mg/mL exceeded the observed Cystone response of 72.50%. EECA also raised urine production and reduced urinary uric acid, particularly at 200 mg/kg. The results of the histopathology showed improved kidney structure. Conclusion: EECA demonstrated anti-crystallization and protective qualities in experimental urolithiasis, encouraging further mechanistic, phytochemical-standardizing, and translational research.

Hypoglycemic Effect of Methanolic Extract of Annona Squmosa L. (Seeds) on Streptozotocin-Induced Diabetes in Rats

with Bhulaxmi
11/17/2026
pp. 1-26

The purity, safety, and long-term therapeutic efficacy of Annona squamosa L. seed extract in the treatment of diabetes were thoroughly assessed. Petroleum ether defatting and Soxhlet methanolic extraction came with the establishment of physicochemical standards (ash values). High levels of total phenolic content (TPC) and total flavonoid content (TFC), which provided notable in vitro antioxidant and anti-glycation properties, were shown by quantitative phytochemical screening. According to OECD Guideline 420 (Fixed Dose Procedure), acute oral toxicity testing verified that the extract has a broad margin of safety, showing no evidence of acute toxicity or fatality up to the highest suggested limit dose. Oral administration of Annona squamosa L. seed extract (200 mg/kg and 400 mg/kg) significantly decreased fasting blood glucose levels and reversed progressive body weight loss in an 8-week in vivo study on streptozotocin (STZ, 50–55 mg/kg)-induced diabetic Wistar rats when compared to untreated diabetic controls. The therapeutic efficacy of the 400 mg/kg dose was similar to that of normal Glibenclamide (10 mg/kg). To sum up, Annona squamosa L. seed methanolic extract is a safe, flavonoid-rich, antioxidant-rich substance that successfully reduces glycation, hyperglycemia, and weight loss in people with chronic diabetes.

Combined Antidepressant Potential of Trigonella Foenum- Graecum and Asparagus Racemosus: A Comprehensive Review

with Yukta Verma
9/8/2026
pp. 76-87

Methanolic extract of Trigonella foenum- graecum (seed) and Asparagus racemosus(root) were studied in the mice and rat both. The study applied the Force Swim Test (FST) and Tail Suspension Test (TST). Poor mood, low energy, oxidative stress, diminished motivation, and compromised emotional functioning are the main symptoms of depression. Depression is the common neuropsychiatric illness. Medicinal plants like T. foenum- graecum and A. racemosus have possible neuroprotective and mood- modulating qualities which has been prompted by the drawbacks of traditional antidepressant medication. Both T.foenum- graecum and A.racemosus have no of physiologically active components and have been shown to have neuropharmacological and adaptogenic effects. The goal of the current investigation was to assess the antidepressant activity of T. foenum- graecum(seed) and A. racemosus (root) using the FST and TST. The purpose of the study was to evaluate the combination formulation behavioral reaction to that of the control and conventional treatment groups. A. racemosus has shown antidepressant like action which is linked to noradrenergic and serotonergic systems, previous experimental research suggest that flavonoids produced from fenugreek can Affect monoaminergic pathways. Therefore, by modifying neurotransmitter function and associated stress- response pathways, the combination formulations may offer a supplementary pharmaceutical strategy. The outcome of this study may offer initial scientific proof in favor of this herbal combination’s further investigation and mechanistic assessment as a viable antidepressant formulation.

Author Statistics
Total Publications:3
Years Active:1
First Publication:2026
Latest Publication:2026
Collaborators:4
Citations:104